Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7246 to 7260 of 7707 results

  1. Antimicrobial prescribing: Ceftazidime/avibactam (ES16)

    This evidence summary has been updated and replaced by NICE antimicrobial health technology evaluation guidance on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.  

    Evidence summary
    Published
    13 November 2017

  2. Preventing recurrence of Clostridium difficile infection: bezlotoxumab (ES13)

    This advice has been updated and replaced by NICE guideline NG199.

    Evidence summary
    Published
    6 June 2017

  3. Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]

    In development [GID-TA10935] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Sepsis (QS161)

    February 2024: We have temporarily withdrawn this quality standard due to ongoing updates to the NICE guideline on sepsis, which underpins the quality statements. See the guidance in development page and guideline in development page for progress on these updates.

    For any queries, please contact qualitystandards@nice.org.uk

    Quality standard
    Last updated
    18 June 2020

  5. Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]

    In development [GID-TA10800] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. High tibial osteotomy with adjustable magnetic nail insertion for symptomatic medial knee osteoarthritis

    Discontinued [GID-IPG10142]

    Interventional procedures guidance
    Discontinued

  7. COVID-19 rapid guideline: severe asthma (NG166)

    May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. See our guidance on treating severe asthma and our guideline on managing COVID-19.

    COVID-19 rapid guideline
    Published
    3 April 2020

  8. Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]

    In development [GID-TA11070] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable [ID5096]

    In development [GID-TA11007] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA696)

    This guidance has been updated and replaced by NICE technology appraisal guidance 984.

    Technology appraisal guidance
    Published
    12 May 2021

  11. Amyotrophic lateral sclerosis - SAR443820 [ID6386]

    In development [GID-TA11476] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Health app: Sleepio for adults with poor sleep (MIB129)

    This advice has been updated and replaced by NICE medical technologies guidance 70.

    Medtech innovation briefing
    Published
    9 November 2017

  13. Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]

    In development [GID-TA11318] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Pembrolizumab with olaparib for maintenance treatment of non-squamous metastatic non-small-cell lung cancer after pembrolizumab with platinum-based chemotherapy [ID4028]

    In development [GID-TA10917] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene for babies 6 months and over to children under 2 years TS ID 11774

    Discontinued [GID-TA11124]

    Technology appraisal guidance
    Discontinued